The First 40 Years of AIDS: Promising Programs, Limited Success.

William W Darrow
Author Information
  1. William W Darrow: Behavioral Research and Evaluation Consultants, LLC, 4552 Post Avenue, Miami Beach, Florida, FL, 33140, USA. darroww@fiu.edu. ORCID

Abstract

HIV-prevention program planning, implementation, and evaluation began in the United States shortly after reports of a mysterious, apparently acquired, immune deficiency syndrome appeared in summer 1981. In San Francisco, New York City, and elsewhere, members of LGBT communities responded by providing accurate information, giving support, and raising money. During the first decade of the AIDS pandemic (1981-1990), social and behavioral scientists contributed by designing theory-based and practical interventions, combining interventions into programs, and measuring impact on behavior change and HIV incidence. In the second decade (1991-2000), federal, state, and local agencies and organizations played a more prominent role in establishing policies and procedures, funding research and programs, and determining the direction of intervention efforts. In the third decade (2001-2010), biomedical interventions were prioritized over behavioral interventions and have dominated attempts in the fourth decade (2011-2020) to integrate biomedical, behavioral, and structural interventions into coherent, efficient, and cost-effective programs to end AIDS.

Keywords

References

  1. J Community Health. 1995 Apr;20(2):87-100 [PMID: 7642797]
  2. Clin Infect Dis. 2018 May 2;66(10):1581-1587 [PMID: 29186421]
  3. Am J Public Health. 2012 Sep;102(9):e9; author reply e9-10 [PMID: 22813470]
  4. N Engl J Med. 2015 Dec 3;373(23):2281-7 [PMID: 26624243]
  5. J Behav Med. 2017 Feb;40(1):6-22 [PMID: 27481101]
  6. J Community Health. 2000 Apr;25(2):95-112 [PMID: 10794204]
  7. JAMA. 1994 Jan 12;271(2):121-7 [PMID: 8264066]
  8. AIDS Behav. 2021 Jan;25(1):284-293 [PMID: 32648064]
  9. JAMA. 1986 Apr 25;255(16):2167-72 [PMID: 3007789]
  10. Soc Sci Med. 1985;21(11):1203-16 [PMID: 3006260]
  11. Public Health Rep. 1998 Jun;113 Suppl 1:75-80 [PMID: 9722812]
  12. Health Educ Q. 1990 Spring;17(1):53-72 [PMID: 2318652]
  13. Sex Transm Dis. 2016 Dec;43(12):725-730 [PMID: 27835623]
  14. AIDS Educ Prev. 2006 Aug;18(4 Suppl A):5-20 [PMID: 16987085]
  15. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e23-8 [PMID: 21694607]
  16. Health Aff (Millwood). 2009 Nov-Dec;28(6):1677-87 [PMID: 19887408]
  17. Am J Public Health. 2012 Nov;102(11):e34-44 [PMID: 22994247]
  18. J Acquir Immune Defic Syndr. 2002 Jul 1;30 Suppl 1:S130-3 [PMID: 12107366]
  19. Epidemiology. 1998 Jul;9(4):365-7 [PMID: 9647895]
  20. JAMA. 2013 Oct 23;310(16):1701-10 [PMID: 24150466]
  21. Int J Drug Policy. 2008 Apr;19 Suppl 1:S65-73 [PMID: 18207726]
  22. Sociol Health Illn. 2015 May;37(4):561-77 [PMID: 25565009]
  23. Am J Community Psychol. 2008 Sep;42(1-2):51-9 [PMID: 18612809]
  24. Soc Sci Med. 1994 Jan;38(1):79-88 [PMID: 8146718]
  25. AIDS Educ Prev. 2006 Aug;18(4 Suppl A):21-31 [PMID: 16987086]
  26. MMWR Morb Mortal Wkly Rep. 1983 Mar 4;32(8):101-3 [PMID: 6403825]
  27. Public Health Rep. 1991 Nov-Dec;106(6):623-7 [PMID: 1659707]
  28. Public Health Rep. 1985 Sep-Oct;100(5):453-5 [PMID: 3931157]
  29. Am J Public Health. 1996 Aug;86(8):1129-36 [PMID: 8712273]
  30. Harm Reduct J. 2017 Jul 26;14(1):51 [PMID: 28747189]
  31. Milbank Q. 2016 Mar;94(1):126-62 [PMID: 26994712]
  32. Emerg Infect Dis. 2018 Mar;24(3):413-416 [PMID: 29460740]
  33. Science. 1983 May 20;220(4599):868-71 [PMID: 6189183]
  34. N Engl J Med. 2018 Jan 25;378(4):314-316 [PMID: 29365298]
  35. MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):597-603 [PMID: 16741496]
  36. Public Health Rep. 1988;103 Suppl 1:1-109 [PMID: 3147481]
  37. J Acquir Immune Defic Syndr. 2017 Feb 1;74 Suppl 2:S75-S80 [PMID: 28079716]
  38. MMWR Suppl. 2011 Oct 7;60(4):64-9 [PMID: 21976168]
  39. Clin Trials. 2017 Aug;14(4):322-332 [PMID: 28627929]
  40. Nature. 2016 Nov 3;539(7627):98-101 [PMID: 27783600]
  41. JAMA. 2019 Mar 5;321(9):844-845 [PMID: 30730529]
  42. J Community Health. 1998 Apr;23(2):113-26 [PMID: 9591203]
  43. AIDS. 2006 Mar 21;20(5):731-9 [PMID: 16514304]
  44. J Acquir Immune Defic Syndr. 2002 Jul 1;30 Suppl 1:S15-29 [PMID: 12107357]
  45. J Acquir Immune Defic Syndr. 2004 Oct 1;37 Suppl 2:S122-5 [PMID: 15385909]
  46. MMWR Morb Mortal Wkly Rep. 1981 Jul 3;30(25):305-8 [PMID: 6789108]
  47. Am J Public Health. 1992 Nov;82(11):1483-9 [PMID: 1443297]
  48. AIDS Behav. 2005 Jun;9(2 Suppl):S87-99 [PMID: 15933830]
  49. Public Health Rep. 2016 Jan-Feb;131(1):52-8 [PMID: 26843670]
  50. Emerg Themes Epidemiol. 2018 May 28;15:7 [PMID: 29872450]
  51. Sex Transm Infect. 2007 Feb;83(1):2-9 [PMID: 17283359]
  52. AIDS. 2008 Aug;22 Suppl 2:S5-8 [PMID: 18641471]
  53. Public Health Rep. 1991 Nov-Dec;106(6):616-22 [PMID: 1720249]
  54. AIDS Behav. 2014 Apr;18(4):625-33 [PMID: 23989823]
  55. JAMA. 1998 Oct 7;280(13):1161-7 [PMID: 9777816]
  56. Public Health Rep. 2016 Jan-Feb;131(1):67-75 [PMID: 26843672]
  57. Curr HIV/AIDS Rep. 2011 Mar;8(1):62-72 [PMID: 20941553]
  58. Public Health Rep. 1991 Nov-Dec;106(6):714-20 [PMID: 1659721]
  59. Sex Transm Dis. 1979 Jan-Mar;6(1):1-4 [PMID: 221992]
  60. Lancet. 1997 Nov 22;350(9090):1500-5 [PMID: 9388397]
  61. Ethn Dis. 2004 Summer;14(3 Suppl 1):S108-16 [PMID: 15682779]
  62. AIDS Behav. 2021 Aug;25(8):2657-2660 [PMID: 33745099]
  63. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18566-70 [PMID: 17978186]
  64. J Acquir Immune Defic Syndr (1988). 1993 Mar;6(3):303-12 [PMID: 8450406]
  65. N Engl J Med. 2005 Dec 1;353(22):2397-402 [PMID: 16319391]
  66. AIDS Behav. 2021 Jun;25(6):1839-1855 [PMID: 33389321]
  67. J Acquir Immune Defic Syndr. 2012 Aug 1;60 Suppl 2:S22-6 [PMID: 22772385]
  68. AIDS Behav. 2014 Apr;18(4):634-7 [PMID: 24057930]
  69. Addiction. 2005 Nov;100(11):1575-6 [PMID: 16277620]
  70. J Public Health Manag Pract. 2015 Nov-Dec;21(6):584-93 [PMID: 26785398]
  71. N Engl J Med. 2015 Dec 3;373(23):2197-9 [PMID: 26624554]
  72. Ethn Dis. 2004 Summer;14(3 Suppl 1):S5-8 [PMID: 15682765]
  73. MMWR Morb Mortal Wkly Rep. 1991 Jun 7;40(22):357 [PMID: 2034201]
  74. J Int AIDS Soc. 2011 Jul 06;14 Suppl 1:S6 [PMID: 21967920]
  75. Sex Transm Infect. 2011 Feb;87(1):2-3 [PMID: 21126962]
  76. JAMA. 1989 Feb 17;261(7):1008-12 [PMID: 2915408]
  77. Lancet. 2004 Jul 3-9;364(9428):41-50 [PMID: 15234855]
  78. Public Health Rep. 1988 May-Jun;103(3):255-60 [PMID: 2836879]
  79. Public Health Rep. 2016 Jan-Feb;131(1):7-10 [PMID: 26843663]
  80. Am J Prev Med. 2016 Oct;51(4 Suppl 2):S140-7 [PMID: 27402185]
  81. Public Health Rep. 2022 Jan-Feb;137(1):32-47 [PMID: 33635724]
  82. Science. 1974 Sep 27;185(4157):1124-31 [PMID: 17835457]
  83. Annu Rev Public Health. 2009;30:175-201 [PMID: 19296775]
  84. Lancet. 2018 Jul 28;392(10144):260-261 [PMID: 30032981]
  85. Am J Public Health. 1991 Feb;81(2):168-71 [PMID: 1990853]
  86. Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S287-92 [PMID: 18190301]
  87. Clin Infect Dis. 2013 Oct;57(8):1164-71 [PMID: 23797289]
  88. AIDS. 2010 Jan 2;24(1):123-37 [PMID: 19770621]
  89. Sex Transm Dis. 1978 Apr-Jun;5(2):51-6 [PMID: 10328031]
  90. AIDS Behav. 2016 Jun;20(6):1143-56 [PMID: 26152607]
  91. Nature. 1987 Mar 12-18;326(6109):137-42 [PMID: 3821890]
  92. J Acquir Immune Defic Syndr. 2015 May 1;69 Suppl 1:S1-7 [PMID: 25867773]
  93. Ann Intern Med. 1983 Aug;99(2):145-51 [PMID: 6603806]
  94. MMWR Morb Mortal Wkly Rep. 2003 Apr 18;52(15):329-32 [PMID: 12733863]
  95. J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):371-381 [PMID: 28418987]
  96. Lancet. 2013 Nov 2;382(9903):1525-33 [PMID: 24152939]
  97. AIDS Res Ther. 2016 Nov 8;13:35 [PMID: 27826353]
  98. Am J Public Health. 1989 Jul;79(7):868-70 [PMID: 2735474]
  99. Ann Intern Med. 2008 Oct 7;149(7):497-508, W96-9 [PMID: 18838730]
  100. Clin Obstet Gynecol. 1975 Mar;18(1):223-32 [PMID: 804364]
  101. Am J Public Health. 1999 Mar;89(3):336-45 [PMID: 10076482]
  102. Sex Transm Dis. 2005 Feb;32(2):130-8 [PMID: 15668621]
  103. Clin Infect Dis. 2011 Mar 15;52(6):793-800 [PMID: 21367734]
  104. MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2 [PMID: 6265753]
  105. Public Health Rep. 1986 Jul-Aug;101(4):341-8 [PMID: 3016789]
  106. Am J Public Health. 2005 Aug;95(8):1439-44 [PMID: 15985649]
  107. Harm Reduct J. 2018 Feb 8;15(1):6 [PMID: 29422042]
  108. Sex Transm Infect. 2002 Apr;78 Suppl 1:i159-63 [PMID: 12083437]
  109. MMWR Recomm Rep. 1996 May 10;45(RR-6):1-24 [PMID: 8606680]
  110. Am J Public Health. 2001 Jul;91(7):1019-24 [PMID: 11441723]
  111. Science. 1988 Feb 5;239(4840):592-6 [PMID: 3340845]
  112. Am J Public Health. 1988 Nov;78(11):1472-4 [PMID: 3177723]
  113. Am J Epidemiol. 1971 Oct;94(4):311-5 [PMID: 5110547]
  114. Am Psychol. 2013 May-Jun;68(4):237-46 [PMID: 23688091]
  115. J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S51-6 [PMID: 22797740]
  116. J Acquir Immune Defic Syndr. 2013 Nov 1;64 Suppl 1:S1-6 [PMID: 23982663]
  117. AIDS Educ Prev. 2006 Aug;18(4 Suppl A):59-73 [PMID: 16987089]

MeSH Term

Acquired Immunodeficiency Syndrome
HIV Infections
Humans
New York City
Organizations
San Francisco
United States

Word Cloud

Created with Highcharts 10.0.0interventionsdecadebehavioralprogramsAIDSchangebiomedicalHIV-preventionprogramplanningimplementationevaluationbeganUnitedStatesshortlyreportsmysteriousapparentlyacquiredimmunedeficiencysyndromeappearedsummer1981SanFranciscoNewYorkCityelsewheremembersLGBTcommunitiesrespondedprovidingaccurateinformationgivingsupportraisingmoneyfirstpandemic1981-1990socialscientistscontributeddesigningtheory-basedpracticalcombiningmeasuringimpactbehaviorHIVincidencesecond1991-2000federalstatelocalagenciesorganizationsplayedprominentroleestablishingpoliciesproceduresfundingresearchdeterminingdirectioninterventioneffortsthird2001-2010prioritizeddominatedattemptsfourth2011-2020integratestructuralcoherentefficientcost-effectiveendFirst40YearsAIDS:PromisingProgramsLimitedSuccessBehaviorImpactInterventionOutcomeRiskReduction

Similar Articles

Cited By